Kunming Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Kunming China (1951)
Status: No NME R&D (1951)

Organization Overview

First Clinical Trial
2018
NCT03396393
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kunming Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

dihydroartemisinin (1 trial)

kpcxm18 (2 trials)

Drugs in Phase 1 Trials (2)

denosumab (prolia) (1 trial)

ky100001 (1 trial)

Drugs in Other Trials (1)

colchicine (colbenemid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5